Wednesday, 15 Aug 2018

You are here

The Fate of Palindromic Rheumatism


Palindromic rheumatism (PR) is an intermittent inflammatory arthropathy with episodes of arthritis and/or periarticular inflammation that wax and wane over time. It is thought that up to one-third of such patients may go on to develop rheumatoid arthritis (RA).

A claims data study from the Taiwanese National Health Insurance Research Database identified 4,421 cases of PR over a 5 year span and compared PR patients to randomly chose 44,210 non-PR individuals who matched (1:10) for age, sex and the year of index date without prior history of  rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjogren's syndrome (SS), dermatomyositis (DM) and polymyositis (PM).

From this cohort, over time 12.9% developed RA, 6.1% developed SS, 2.6% developed SLE,  and less than 1% developed SSc, PM, or DM.

PR patients had an increased risk of RA (HR, 118.76; 95% CI, 89.81-157.04), SS (HR, 59.57; 95% CI, 43.87-80.88), SLE (HR, 51.56; 95% CI, 32.96-80.66) PM (HR, 57.38; 95% CI, 6.90-476.83), and SSc (HR, 13.42; 95% CI, 3.79-47.55) but not of DM (HR, 3.44; 95% CI, 0.34-34.59).

Patients with PR had an increased risk of developing RA, SS, SLE, PM, and SSc.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Maternal RA Increases Offspring Risk of Autoimmune Disorders

A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.

Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis

A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.  

The Lung in RA: Little Progress

The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society of Rheumatology.